Anti-proliferative activity of the NPM1 interacting natural product avrainvillamide in acute myeloid leukemia

DSpace/Manakin Repository

Anti-proliferative activity of the NPM1 interacting natural product avrainvillamide in acute myeloid leukemia

Citable link to this page

 

 
Title: Anti-proliferative activity of the NPM1 interacting natural product avrainvillamide in acute myeloid leukemia
Author: Andresen, Vibeke; Erikstein, Bjarte S; Mukherjee, Herschel; Sulen, André; Popa, Mihaela; Sørnes, Steinar; Reikvam, Håkon; Chan, Kok-Ping; Hovland, Randi; McCormack, Emmet; Bruserud, Øystein; Myers, Andrew G; Gjertsen, Bjørn T

Note: Order does not necessarily reflect citation order of authors.

Citation: Andresen, V., B. S. Erikstein, H. Mukherjee, A. Sulen, M. Popa, S. Sørnes, H. Reikvam, et al. 2016. “Anti-proliferative activity of the NPM1 interacting natural product avrainvillamide in acute myeloid leukemia.” Cell Death & Disease 7 (12): e2497. doi:10.1038/cddis.2016.392. http://dx.doi.org/10.1038/cddis.2016.392.
Full Text & Related Files:
Abstract: Mutated nucleophosmin 1 (NPM1) acts as a proto-oncogene and is present in ~30% of patients with acute myeloid leukemia (AML). Here we examined the in vitro and in vivo anti-leukemic activity of the NPM1 and chromosome region maintenance 1 homolog (CRM1) interacting natural product avrainvillamide (AVA) and a fully syntetic AVA analog. The NPM1-mutated cell line OCI-AML3 and normal karyotype primary AML cells with NPM1 mutations were significantly more sensitive towards AVA than cells expressing wild-type (wt) NPM1. Furthermore, the presence of wt p53 sensitized cells toward AVA. Cells exhibiting fms-like tyrosine kinase 3 (FLT3) internal tandem duplication mutations also displayed a trend toward increased sensitivity to AVA. AVA treatment induced nuclear retention of the NPM1 mutant protein (NPMc+) in OCI-AML3 cells and primary AML cells, caused proteasomal degradation of NPMc+ and the nuclear export factor CRM1 and downregulated wt FLT3 protein. In addition, both AVA and its analog induced differentiation of OCI-AML3 cells together with an increased phagocytotic activity and oxidative burst potential. Finally, the AVA analog displayed anti-proliferative activity against subcutaneous xenografted HCT-116 and OCI-AML3 cells in mice. Our results demonstrate that AVA displays enhanced potency against defined subsets of AML cells, suggesting that therapeutic intervention employing AVA or related compounds may be feasible.
Published Version: doi:10.1038/cddis.2016.392
Other Sources: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5260983/pdf/
Terms of Use: This article is made available under the terms and conditions applicable to Other Posted Material, as set forth at http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAA
Citable link to this page: http://nrs.harvard.edu/urn-3:HUL.InstRepos:30371137
Downloads of this work:

Show full Dublin Core record

This item appears in the following Collection(s)

 
 

Search DASH


Advanced Search
 
 

Submitters